日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

2型糖尿病常规治疗中应用GLP-1受体激动剂或基础胰岛素后的心血管结局:一项区域性回顾性研究

Longato, Enrico; Di Camillo, Barbara; Sparacino, Giovanni; Tramontan, Lara; Avogaro, Angelo; Fadini, Gian Paolo

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

临床实践表明,与使用DPP-4抑制剂治疗的2型糖尿病患者相比,使用GLP-1受体激动剂治疗的2型糖尿病患者心血管预后更佳。

Longato, Enrico; Di Camillo, Barbara; Sparacino, Giovanni; Tramontan, Lara; Avogaro, Angelo; Fadini, Gian Paolo

Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study

二肽基肽酶-4抑制剂暴露与2型糖尿病患者感染COVID-19的关系:一项病例对照研究

Fadini, Gian Paolo; Morieri, Mario Luca; Longato, Enrico; Bonora, Benedetta Maria; Pinelli, Silvia; Selmin, Elisa; Voltan, Giacomo; Falaguasta, Daniele; Tresso, Silvia; Costantini, Giorgia; Sparacino, Giovanni; Di Camillo, Barbara; Tramontan, Lara; Cattelan, Anna Maria; Vianello, Andrea; Fioretto, Paola; Vettor, Roberto; Avogaro, Angelo